-

Orthofix Announces Election of Jason Hannon to Board of Directors

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc., (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that Jason M. Hannon has been elected by its shareholders to the Company’s Board of Directors. A seasoned medical device executive, Hannon is currently the Chief Executive Officer of Mainstay Medical International plc, a global company headquartered in Ireland focused on bringing to market the ReActiv8, an implantable restorative neurostimulation system to treat disabling chronic low back pain.

“We are very pleased that Jason is joining the Orthofix Board of Directors,” said Ron Matricaria, Chairman of the Board. “We feel his broad experience in the medical device industry and specifically his expertise in Spine will bring valuable industry insights to the Company.”

Hannon has also served as President and Chief Operating Officer of NuVasive, Inc. Over the course of 12 years at NuVasive, he held various roles of increasing responsibility, including as Executive Vice President, International; and Executive Vice President, Corporate Development; and General Counsel. During Hannon’s tenure, he led initiatives to expand product launches, revamp the commercialization process for global development and structured multiple strategic partnerships and acquisitions.

Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

About Orthofix

Orthofix Medical Inc. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in more than 70 countries via the Company's sales representatives and distributors. For more information, please visit www.orthofix.com.

Contacts

Mark Quick
Investor Relations
214-937-2924
markquick@orthofix.com

Denise Landry
Media Relations
214-937-2529
deniselandry@orthofix.com

Orthofix Medical Inc.

NASDAQ:OFIX

Release Summary
Orthofix Medical Inc., elects medical device executive Jason Hannon to the Company’s Board of Directors.
Release Versions

Contacts

Mark Quick
Investor Relations
214-937-2924
markquick@orthofix.com

Denise Landry
Media Relations
214-937-2529
deniselandry@orthofix.com

Social Media Profiles
More News From Orthofix Medical Inc.

Orthofix Reports Third Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6™ product lines. Highlights Third quarter...

Orthofix to Participate in Upcoming Investor Conferences

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL, November 11, 2025, at 1:15 pm Eastern Time Stifel Healthcare Conference in New York, NY, November 12, 2025, at 10:00 am Eastern Time Jefferies...

Orthofix to Report Third Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referenci...
Back to Newsroom